All In Biotech

Drug Trial Radar · NCT06514976

Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy

Multi-center International Observational Study of Efficiency of the Drug Cytoflavin®, Solution for Infusions in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy.

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

562

Planned (sponsor's estimate)

Start

Mar 1, 2024

Primary completion

Jun 1, 2027

Study completion Aug 1, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 23, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Stroke remains one of the main socially significant problems in the healthcare in the third millennium. The lethality in persons with history of stroke by the end of the 1st year of disease is high. A trend to increased frequency of stroke in the young age is observed during the last decade; third of patients is working-age individuals, out of whom only 15-20% returns to labor, and others remain disabled persons requiring constant medical and social support

Conditions

  • Stroke, Acute
  • Stroke, Ischemic

Interventions

  • CytoflavinDrug

    Cytoflavin solution for infusions. 20-40 ml/day (10 ml with the interval of 8-12 hours for 10 days; the single dose is increased up to 20 ml in case of the severe form of the disease) by intravenous drop infusion in dilution per 100-200 ml of 0.9% sodium chloride solution for 10 days; rate of administration: 3-4 ml/min

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with favorable functional outcome (score 0-2) according to Modified Rankin Scale (mRS) on Day of Discharge (assessment at Visit 4 or Visit 5, on Day of Discharge) and on Day 90;Time frame: Base, day 14, day 21, day 90

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • "Ivanovo Regional Clinical Hospital"

    Ivanovo, Russia · Recruiting

  • Kazan State Medical University

    Kazan', Russia · Recruiting

  • State Autonomous Institution of Health Interregional clinical diagnostic center

    Kazan', Russia · Recruiting

  • Moscow City Clinical Hospital No.64 (CCH named after V.V. Vinogradov)

    Moscow, Russia · Recruiting

  • N.I. Pirogov City Clinical Hospital No. 1

    Moscow, Russia · Recruiting

  • Vorohobov's City Clinical Hospital №67

    Moscow, Russia · Recruiting

  • City Clinical Hospital No. 1 Novosibirsk

    Novosibirsk, Russia · Recruiting

  • Alexandrovskaya hospital

    Saint Petersburg, Russia · Recruiting

  • Almazov National Medical Research Centr

    Saint Petersburg, Russia · Recruiting

  • City Mariinsky Hospital

    Saint Petersburg, Russia · Recruiting

  • Nikolaevskaya Hospital

    Saint Petersburg, Russia · Recruiting

  • Saint-Petersburg I. I. Dzhanelidze research institute of emergency medicine

    Saint Petersburg, Russia · Recruiting

  • St. Petersburg State Budgetary Institution of Public Health "City Hospital No. 40 of Kurortny District"

    Saint Petersburg, Russia · Recruiting

  • The City Hospital of the Holy Martyr Elizabeth

    Saint Petersburg, Russia · Recruiting

  • Smolensk Regional Clinical Hospital

    Smolensk, Russia · Recruiting

  • Municipal Clinical Hospital #13, the City of Ufa, State Budgetary Healthcare Institution of the Republic of Bashkortostan

    Ufa, Russia · Recruiting

  • Budgetary healthcare institution of the Voronezh region "Voronezh Regional Clinical Hospital No. 1"

    Voronezh, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.